Figures & data
Figure 1. Flow chart of the patient selection. HCC: hepatocellular carcinoma; HR: hepatic resection; ECOG: Eastern Cooperative Oncology Group; MVI: microvascular invasion; RFA: radiofrequency ablation; TACE: transarterial chemoembolization.
![Figure 1. Flow chart of the patient selection. HCC: hepatocellular carcinoma; HR: hepatic resection; ECOG: Eastern Cooperative Oncology Group; MVI: microvascular invasion; RFA: radiofrequency ablation; TACE: transarterial chemoembolization.](/cms/asset/917d0c8d-9489-41df-811e-d94c70a0134b/ihyt_a_2051613_f0001_c.jpg)
Table 1. Baseline characteristics of recurrent HCC patients with MVI-positive primary tumor who had undergone neoadjuvant TACE with RFA or RFA alone.
Figure 2. Kaplan-Meier curves of the survival outcomes of patients with solitary small recurrent HCC with MVI-positive primary tumor who were treated with neoadjuvant TACE and RFA or RFA alone. Kaplan-Meier curves of overall survival (A) and recurrence-free survival (B) for patients who underwent neoadjuvant TACE and RFA or RFA alone. HCC: hepatocellular carcinoma; MVI: microvascular invasion; TACE: transarterial chemoembolization; RFA: radiofrequency ablation.
![Figure 2. Kaplan-Meier curves of the survival outcomes of patients with solitary small recurrent HCC with MVI-positive primary tumor who were treated with neoadjuvant TACE and RFA or RFA alone. Kaplan-Meier curves of overall survival (A) and recurrence-free survival (B) for patients who underwent neoadjuvant TACE and RFA or RFA alone. HCC: hepatocellular carcinoma; MVI: microvascular invasion; TACE: transarterial chemoembolization; RFA: radiofrequency ablation.](/cms/asset/b06e341e-34a1-4d97-add1-fe8d8750102d/ihyt_a_2051613_f0002_c.jpg)
Figure 3. The hazard ratio of overall survival and recurrence-free survival for patients with solitary small recurrent HCC with MVI-positive primary tumor who were treated with neoadjuvant TACE and RFA or RFA alone in different subgroups stratified by clinical parameters. (A) for overall survival; (B) for recurrence-free survival. HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; ALB: albumin; ALBI: albumin bilirubin; AFP: alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer; TACE: transarterial chemoembolization; RFA: radiofrequency ablation.
![Figure 3. The hazard ratio of overall survival and recurrence-free survival for patients with solitary small recurrent HCC with MVI-positive primary tumor who were treated with neoadjuvant TACE and RFA or RFA alone in different subgroups stratified by clinical parameters. (A) for overall survival; (B) for recurrence-free survival. HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; ALB: albumin; ALBI: albumin bilirubin; AFP: alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer; TACE: transarterial chemoembolization; RFA: radiofrequency ablation.](/cms/asset/4c10686a-169e-4d2b-9013-4994c36b582f/ihyt_a_2051613_f0003_b.jpg)
Table 2. Univariable and multivariable analyses of predictors of overall survival and recurrence-free survival for recurrent HCC patients with MVI-positive primary tumor.
Figure 4. Recurrences after the treatments for recurrent HCC patients with MVI-positive primary tumor, and treatment modalities for subsequent recurrences in patients with solitary small recurrent hepatocellular carcinoma. (A) for patients who underwent adjuvant TACE and RFA; (B) for patients who underwent RFA alone. HCC: hepatocellular carcinoma; TACE: transarterial chemoembolization; RFA: radiofrequency ablation; ER: extrahepatic recurrence, IR: intrahepatic recurrence.
![Figure 4. Recurrences after the treatments for recurrent HCC patients with MVI-positive primary tumor, and treatment modalities for subsequent recurrences in patients with solitary small recurrent hepatocellular carcinoma. (A) for patients who underwent adjuvant TACE and RFA; (B) for patients who underwent RFA alone. HCC: hepatocellular carcinoma; TACE: transarterial chemoembolization; RFA: radiofrequency ablation; ER: extrahepatic recurrence, IR: intrahepatic recurrence.](/cms/asset/826948f9-56f1-44c8-841a-b158a31c798b/ihyt_a_2051613_f0004_c.jpg)
Table 3. Complications after treatment.